Advertisement

Journal of Assisted Reproduction and Genetics

, Volume 34, Issue 4, pp 517–524 | Cite as

Genetic analysis of the M2/ANXA5 haplotype as recurrent pregnancy loss predisposition in the Malay population

  • Kai-Cheen Ang
  • Sushilnathan Kathirgamanathan
  • Ewe Seng Ch’ng
  • Yan-Yeow Lee
  • Anna-Liza Roslani
  • Bavanandan Naidu
  • Krishna Kumar
  • Ridzuan Abdullah
  • Siti-Nadiah Abdul Kadir
  • Narazah Mohd Yusoff
  • Wan Zaidah Abdullah
  • Nadja Bogdanova
  • Peter Wieacker
  • Arseni Markoff
  • Thean-Hock Tang
Genetics

Abstract

Purpose

The aim of this study was to evaluate a new predisposition factor, M2/ANXA5 (RPRGL3), in recurrent pregnancy loss (RPL) patients of Malay origin, since it was previously known that the prevalence of this condition is relatively high among the Malay population of Malaysia, where conventional hereditary thrombophilia factors have been generally ruled out.

Methods

A total of 232 women who had experienced ≥2 unexplained RPL and 141 available male partners were recruited, with 360 healthy Malay and 166 parous female controls. Prevalence of M2 carriage and RPL odds ratios were calculated in (a) control and patient groups; (b) clinically defined subgroups in categories of pregnancy loss, primary, secondary, and tertiary; and (c) timing of pregnancy loss in early, ≤15th gestation week and “late” fetal losses, and >15th gestation week subgroups.

Results

Both male and female subjects had similar M2/ANXA5 allele frequencies. The carrier rate of M2/ANXA5 for the general Malay population was 42.2 and 34.9% for parous controls. These carrier rates compared to Malay RPL subjects (52% M2 carriers) resulted in elevated odds ratios (95% confidence interval) of 1.53 (1.1 to 2.1) and 1.97 (1.3 to 3.1) accordingly for early fetal losses. Moreover, exceeding copy numbers of M2/ANXA5 alleles seemed to afflict a greater chance of RPL in couples, especially when both partners were M2 carriers.

Conclusion

This study confirmed the proposed role of M2/ANXA5 as embryonic, genetically associated thrombophilia predisposition factor for early RPL among ethnic Malay of Malaysia.

Keywords

Annexin A5 M2/ANXA5 Recurrent pregnancy loss (RPL) Miscarriage 

Notes

Acknowledgements

The authors thank the women and their partners who participated in this study.

Compliance with ethical standards

The present genetic association study was approved by the Human Ethics Research Committee of the Universiti Sains Malaysia (USMKK/PPP/JEPeM [245.3.(2)]) and from the National Institutes of Health, Ministry of Health, Malaysia (NMRR-11-1044-9519). The study was carried out in accordance with The Code of Ethics of the World Health Organization (Declaration of Helsinki), and the criteria of strengthening the reporting of genetic association studies were observed as far as applicable. The volunteer subjects who agreed to participate have signed an informed consent before collection of peripheral blood samples. Random Malay population subjects were recruited at the Universiti Sains Malaysia, Penang campus from January 2011 to May 2013 with appropriate informed consent.

Funding

This work was supported by Universiti Sains Malaysia Research Universiti Grant (USM RU grant no: 1001/CIPPT/812100) awarded to TTH. AM was funded by a PI grant of the German Research Community, DFG, MA-6288/1-1. AKC was supported by MyBrain15 Program (KPM (b) 850304015158) under the Malaysian Ministry of Education.

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

10815_2017_871_MOESM1_ESM.docx (55 kb)
Supplementary Table S1 (DOCX 54 kb)
10815_2017_871_MOESM2_ESM.docx (56 kb)
Supplementary Table S2 (DOCX 55 kb)
10815_2017_871_Fig3_ESM.gif (91 kb)
Supplementary Fig. S1

AS-PCR- lane 1: negative control (1st PCR); lanes 2 and 3: negative control (2nd PCR) for ‘normal’ and M2/ANXA5 specific primers; lanes 4: M2 heterozygous DNA template; lanes 5: DNA sample of a ‘normal’ genotype; lanes 6: M2 homozygous DNA template. Double lanes 4, 5 and 6: 1st track is specific for the ‘normal’ allele, 2nd track discriminates the M2 haplotype. (GIF 91 kb)

10815_2017_871_MOESM3_ESM.tiff (1.5 mb)
High resolution image (TIFF 1495 kb)

References

  1. 1.
    Sutan R, Miskam HM. Psychosocial impact of perinatal loss among Muslim women. BMC Womens Health. 2012;12:1–9.CrossRefGoogle Scholar
  2. 2.
    Kutteh WH, Park VM, Deitcher SR. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril. 1999;71:1048–53.CrossRefPubMedGoogle Scholar
  3. 3.
    Grandone E, Margaglione M. Inherited thrombophilia and gestational vascular complications. Best Pract Res Clin Haematol. 2003;16:321–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Tiscia G, Colaizzo D, Chinni E, Pisanelli D, Sciannamè N, Favuzzi G, et al. Haplotype M2 in the annexin A5 (ANXA5) gene and the occurrence of obstetric complications. Thromb Haemost. 2009;102:309–13.PubMedGoogle Scholar
  5. 5.
    Tüttelmann F, Ivanov P, Dietzel C, Sofroniou A, Tsvyatkovska TM, Komsa-Penkova RS, et al. Further insights into the role of the annexin A5 M2 haplotype as recurrent pregnancy loss factor, assessing timing of miscarriage and partner risk. Fertil Steril. 2013;100:1321–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Younis JS, Samueloff A. Gestational vascular complications. Best Pract Res Clin Haematol. 2003;16:135–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Bogdanova N, Markoff A. Hereditary thrombophilic risk factors for recurrent pregnancy loss. J Community Genet. 2010;1:47–53.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706–8.PubMedGoogle Scholar
  9. 9.
    De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost. 1998;24:367–79.CrossRefPubMedGoogle Scholar
  10. 10.
    Arshat H, Tan Boon A, Tey Nai P. The effects of life cycle and family formation variables on pregnancy outcome. Malaysian journal of reproductive health: a publication of the Reproductive Research Centre of the National Population and Family Development Board, Malaysia. 1985;3:115–25Google Scholar
  11. 11.
    Ayadurai T, Muniandy S, Omar SZ. Thrombophilia investigation in Malaysian women with recurrent pregnancy loss. J Obstet Gynaecol Res. 2009;35:1061–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Yusoff NM, Abdullah WZ, Ghazali S, Othman MS, Baba AA, Abdullah N, et al. The absence of factor V Leiden mutation in Malays with recurrent spontaneous abortions. Aust N Z J Obstet Gynaecol. 2002;42:164–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Tey NP, Ng ST, Yew SY. Proximate determinants of fertility in Peninsular Malaysia. Asia Pac J Public Health. 2012;24:495–505.CrossRefPubMedGoogle Scholar
  14. 14.
    Bogdanova N, Horst J, Chlystun M, Croucher PJ, Nebel A, Bohring A, et al. A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss. Hum Mol Genet. 2007;16:573–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Rand JH, Wu X-X, Quinn AS, Chen PP, McCrae KR, Bovill EG, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol. 2003;163:1193–200.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Tiscia GL, Dørum E, Myklebust CF, Grandone E, Sandset PM, Skretting G. Functional characterization of annexin A5 gene promoter allelic variants. Thromb Res. 2016;144:93–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Chinni E, Tiscia GL, Colaizzo D, Vergura P, Margaglione M, Grandone E. Annexin V expression in human placenta is influenced by the carriership of the common haplotype M2. Fertil Steril. 2009;91:940–2.CrossRefPubMedGoogle Scholar
  18. 18.
    Markoff A, Gerdes S, Feldner S, Bogdanova N, Gerke V, Grandone E. Reduced allele specific annexin A5 mRNA levels in placentas carrying the M2/ANXA5 allele. Placenta. 2010;31:937–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Ota S, Miyamura H, Nishizawa H, Inagaki H, Inagaki A, Inuzuka H, et al. Contribution of fetal ANXA5 gene promoter polymorphisms to the onset of pre-eclampsia. Placenta. 2013;34:1202–10.CrossRefPubMedGoogle Scholar
  20. 20.
    Miyamura H, Nishizawa H, Ota S, Suzuki M, Inagaki A, Egusa H, et al. Polymorphisms in the annexin A5 gene promoter in Japanese women with recurrent pregnancy loss. Mol Hum Reprod. 2011;17:447–52.CrossRefPubMedGoogle Scholar
  21. 21.
    Rogenhofer N, Engels L, Bogdanova N, Tüttelmann F, Markoff A, Thaler C. Paternal and maternal carriage of the annexin A5 M2 haplotype are equal risk factors for recurrent pregnancy loss: a pilot study. Fertil Steril. 2012;98:383–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Demetriou C, Abu-Amero S, White S, Peskett E, Markoff A, Stanier P, et al. Investigation of the annexin A5 M2 haplotype in 500 white European couples who have experienced recurrent spontaneous abortion. Reprod BioMed Online. 2015;31:681–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Thean Hock T, Bogdanova N, Kai Cheen A, Kathirgamanathan S, Bin Abdullah R, Mohd Yusoff N, et al. M2/ANXA5 haplotype as a predisposition factor in Malay women and couples experiencing recurrent spontaneous abortion: a pilot study. Reprod BioMed Online. 2015;30:434–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Li TC, Makris M, Tomsu M, Tuckerman E, Laird S. Recurrent miscarriage: aetiology, management and prognosis. Hum Reprod Update. 2002;8:463–81.CrossRefPubMedGoogle Scholar
  25. 25.
    The Rotterdam Eshre/Asrm-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.Google Scholar
  26. 26.
    Kagan KO, Sonek J, Berg X, Berg C, Mallmann M, Abele H, et al. Facial markers in second- and third-trimester fetuses with trisomy 18 or 13, triploidy or Turner syndrome. Ultrasound Obstet Gynecol. 2015;46:60–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Carp H, editor. Recurrent pregnancy loss: causes, controversies and treatment. London: CRC Press; 2007.Google Scholar
  28. 28.
    Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril. 2008;89:1603.CrossRefGoogle Scholar
  29. 29.
    Rousset F. genepop’007: a complete re-implementation of the genepop software for Windows and Linux. Mol Ecol Resour. 2008;8:103–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Nagirnaja L, Nõmmemees D, Rull K, Christiansen OB, Nielsen HS, Laan M. Annexin A5 promoter haplotype M2 is not a risk factor for recurrent pregnancy loss in Northern Europe. PLoS One. 2015;10:e0131606.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Soares PA, Trejaut JA, Rito T, Cavadas B, Hill C, Eng KK, et al. Resolving the ancestry of Austronesian-speaking populations. Hum Genet. 2016;135:309–26.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Irwan NM. Prevalence and risk factors of pregnancy loss in Malaysia. 2nd International Conference on Demography and Population Studies, 2015; Athens, Greece.Google Scholar
  33. 33.
    Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ. 1997;315:32–4.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Roqué H, Paidas MJ, Funai EF, Kuczynski E, Lockwood CJ. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost. 2004;91:290–5.PubMedGoogle Scholar
  35. 35.
    Rogenhofer N, Markoff A, Wagner A, Klein HG, Petroff D, Schleussner E, et al. Lessons from the EThIGII trial: proper putative benefit assessment of low-molecular-weight heparin treatment in M2/ANXA5 haplotype carriers. Clinical and Applied Thrombosis/Hemostasis. 2016.Google Scholar
  36. 36.
    Fishel S, Baker D, Elson J, Ragunath M, Atkinson G, Shaker A, et al. Precision medicine in assisted conception: a multicenter observational treatment cohort study of the annexin A5 M2 haplotype as a biomarker for antithrombotic treatment to improve pregnancy outcome. EBioMedicine. 2016;10:298–304.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Kai-Cheen Ang
    • 1
  • Sushilnathan Kathirgamanathan
    • 2
  • Ewe Seng Ch’ng
    • 1
  • Yan-Yeow Lee
    • 3
  • Anna-Liza Roslani
    • 4
  • Bavanandan Naidu
    • 5
  • Krishna Kumar
    • 3
  • Ridzuan Abdullah
    • 2
  • Siti-Nadiah Abdul Kadir
    • 6
  • Narazah Mohd Yusoff
    • 1
  • Wan Zaidah Abdullah
    • 7
  • Nadja Bogdanova
    • 8
  • Peter Wieacker
    • 8
  • Arseni Markoff
    • 8
  • Thean-Hock Tang
    • 1
    • 9
  1. 1.Advanced Medical and Dental InstituteUniversity Sains MalaysiaBertamMalaysia
  2. 2.Department of Obstetrics and GynaecologyHospital Sultan Abdul HalimSungai PetaniMalaysia
  3. 3.Department of Obstetrics and GynaecologyHospital Tuanku JaafarSerembanMalaysia
  4. 4.Department of Obstetrics and GynaecologyHospital Tengku Ampuan AfzanKuantanMalaysia
  5. 5.Department of Obstetrics and GynaecologyHospital Sultanah BahiyahAlor SetarMalaysia
  6. 6.Department of PathologyHospital Sultan Abdul HalimSungai PetaniMalaysia
  7. 7.Department of Haematology, School of Medical SciencesUniversiti Sains MalaysiaKubang KerianMalaysia
  8. 8.Institute of Human GeneticsUniversity of MuensterMuensterGermany
  9. 9.Advanced Medical and Dental Institute (AMDI)Universiti Sains MalaysiaKepala BatasMalaysia

Personalised recommendations